The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...

Cigna's Evernorth is rolling out a new pharmacy benefit management program that caps members' monthly cost for key GLP-1 ...

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...

Cigna subsidiary Evernorth Health Services will automate prior authorizations for GLP-1 weight-loss drugs under a new program ...

Health plan sponsors are also expected to see a reduction in the net cost per prescription of GLP-1 medications to treat obesity.

The Cigna Group (NYSE:CI)’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit ...

Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an ...

Evernorth, the health services division of The Cigna Group (NYSE: CI) announced a first-of-its-kind pharmacy benefit offering that make weight loss medications WEGOVY® and ZEPBOUND® more available to ...

Cigna’s (NYSE:CI) health services arm, Evernorth, has launched a pharmacy benefit program that caps out-of-pocket costs at $200 per month for patients using the weight-loss drugs - Wegovy from Novo ...

Cigna's pricing compares to the cash-pay market for weight-loss drugs, said Harold Carter, a senior vice president at Evernorth ... In clinical trials, Wegovy and Zepbound led to a 15% to 20% ...